| Ident. | Authors (with country if any) | Title |
|---|
| 000164 (2020) |
Giulia Cassone ; Andreina Manfredi ; Fabiola Atzeni ; Vincenzo Venerito ; Caterina Vacchi ; Valentina Picerno ; Federica Furini ; Gian Luca Erre ; Paola Tomietto ; Anna Laura Fedele [Italie] ; Giovanni Della Casa [Italie] ; Valeria Nucera ; Chiara Giannitti [Italie] ; Carlo Salvarani ; Marco Sebastiani | Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study |
| 000293 (2020) |
Hermine I. Brunner [États-Unis] ; Nikolay Tzaribachev [Allemagne] ; Gabriel Vega Cornejo ; Rik Joos [Belgique] ; Elisabeth Gervais [France] ; Rolando Cimaz [Italie] ; Inmaculada Calvo Penadés [Espagne] ; Rubén Cuttica [Argentine] ; Thomas Lutz [Allemagne] ; Pierre Quartier [France] ; Yash Gandhi [États-Unis] ; Marleen Nys [Belgique] ; Robert Wong [États-Unis] ; Alberto Martini [Italie] ; Daniel J. Lovell [États-Unis] ; Nicolino Ruperto [Italie] | Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept |
| 000432 (2020) |
Kosuke Ebina [Japon] ; Toru Hirano [Japon] ; Yuichi Maeda [Japon] ; Wataru Yamamoto [Japon] ; Motomu Hashimoto [Japon] ; Koichi Murata [Japon] ; Tohru Takeuchi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Akira Onishi [Japon] ; Sadao Jinno [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Keiichi Yamamoto [Japon] ; Atsushi Kumanogoh [Japon] ; Makoto Hirao [Japon] | Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study. |
| 000599 (2020) |
Giovanni Cagnotto [Suède] ; Minna Willim [Suède] ; Jan- Ke Nilsson [Suède] ; Michele Compagno [Suède] ; Lennart T. H. Jacobsson [Suède] ; Saedis Saevarsdottir [Suède] ; Carl Turesson [Suède] | Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register |
| 000616 (2019-06-12) |
Kedra Joanna [France] ; Philippe Dieudé [France] ; Hubert Marotte [États-Unis] ; Alexandre Lafourcade [France] ; Emilie Ducourau [France] ; Thierry Schaeverbeke [France] ; Aleth Perdriger [France] ; Martin Soubrier [France] ; Jacques Morel [France] ; Arnaud Constantin [Royaume-Uni] ; Emmanuelle Dernis [France] ; Valérie Royant [France] ; Jean-Hugues Salmon [France] ; Thao Pham [France] ; Jacques-Eric Gottenberg [France] ; Edouard Pertuiset [France] ; Maxime Dougados [France] ; Valérie Devauchelle-Pensec [France] ; Philippe Gaudin [France] ; Gregoire Cormier [France] ; Philippe Goupille [France] ; Xavier Mariette [France] ; Francis Berenbaum [France] ; Didier Alcaix [France] ; Sid Ahmed Rouidi [France] ; Jean-Marie Berthelot [France] ; Agnès Monnier [France] ; Christine Piroth [France] ; Frederic Liote [France] ; Vincent Goeb [France] ; Cécile Gaujoux-Viala [France] ; Isabelle Chary Valckenaere [France] ; David Hajage [France] ; Florence Tubach [France] ; Bruno Fautrel [France] | Towards the lowest efficacious dose (toledo): results of a multicenter non-inferiority randomized open-label controlled trial assessing tocilizumab or abatacept injection spacing in rheumatoid arthritis patients in remission |
| 000866 (2019) |
Gulsen Ozen [États-Unis] ; Sofia Pedro [États-Unis] ; Rebecca Schumacher [États-Unis] ; Teresa A. Simon [États-Unis] ; Kaleb Michaud [États-Unis] | Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study |
| 000881 (2019) |
Kathrine Lederballe Gr N [Oman] ; Elizabeth V. Arkema [Suède] ; Bente Glintborg [Danemark] ; Frank Mehnert [Danemark] ; Mikkel Stergaard [Danemark] ; Lene Dreyer [Danemark] ; Mette N Rgaard [Danemark] ; Niels Steen Krogh [Danemark] ; Johan Askling [Suède] ; Merete Lund Hetland [Danemark] | Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden. |
| 000987 (2019) |
Denis Choquette [Canada] ; Louis Bessette [Canada] ; Evo Alemao [États-Unis] ; Boulos Haraoui [Canada] ; Roelien Postema [Royaume-Uni] ; Jean-Pierre Raynauld [Canada] ; Louis Coupal [Canada] | Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry |
| 000A16 (2019) |
Kathrine L. Gr N [Danemark] ; Bente Glintborg [Danemark] ; Mette N Rgaard ; Frank Mehnert ; Mikkel Stergaard [Danemark] ; Lene Dreyer ; Niels S. Krogh [Danemark] ; Merete L. Hetland [Danemark] | Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study. |
| 000D17 (2019) |
Samah Hamdy Elmedany [Égypte] ; Aly Elsayed Mohamed [Égypte] ; Sahar Mahfouz Abdel Galil [Égypte] | Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis. |
| 000E15 (2019) |
Saara Huoponen [Finlande] ; Kalle J. Aaltonen [Finlande] ; Jaana Viikinkoski [Finlande] ; Jarno Rutanen [Finlande] ; Heikki Relas [Finlande] ; Kirsi Taimen [Finlande] ; Kari Puolakka [Finlande] ; Dan Nordström [Finlande] ; Marja Blom [Finlande] | Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis |
| 000E35 (2019) |
Yi-Ming Chen [Taïwan] ; Wen-Nan Huang [Taïwan] ; Tsai-Ling Liao [Taïwan] ; Jun-Pen Chen [Taïwan] ; Sheng-Shun Yang [Taïwan] ; Hsin-Hua Chen [Taïwan] ; Tsu-Yi Hsieh [Taïwan] ; Wei-Ting Hung [Taïwan] ; Yi-Hsing Chen [Taïwan] ; Der-Yuan Chen [Taïwan] | Comparisons of hepatitis C viral replication in patients with rheumatoid arthritis receiving tocilizumab, abatacept and tofacitinib therapy. |
| 000E46 (2019) |
Teresa A. Simon [États-Unis] ; Maarten Boers [Pays-Bas] ; Marc Hochberg [États-Unis] ; Nicole Baker [États-Unis] ; Mary L. Skovron [États-Unis] ; Nitesh Ray ; Sanket Singhal ; Samy Suissa ; Andres Gomez-Caminero [États-Unis] | Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study |
| 000E47 (2019) |
Jacques-Eric Gottenberg [France] ; Jacques Morel [France] ; Elodie Perrodeau [France] ; Thomas Bardin [France] ; Bernard Combe [France] ; Maxime Dougados [France] ; Rene-Marc Flipo [France] ; Alain Saraux [France] ; Thierry Schaeverbeke [France] ; Jean Sibilia [France] ; Martin Soubrier [France] ; Olivier Vittecoq [France] ; Gabriel Baron [France] ; Arnaud Constantin [France] ; Philippe Ravaud [France] ; Xavier Mariette [France] | Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study |
| 000E48 (2019) |
Thomas Frisell [Suède] ; Mats Dehlin ; Daniela Di Giuseppe [Suède] ; Nils Feltelius ; Carl Turesson ; Johan Askling [Suède] | Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. |
| 000E52 (2019) |
Thomas Frisell [Suède] ; Johan Askling [Suède] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. |
| 000E53 (2019) |
Thomas Frisell [Suède] ; Johan Askling [Suède] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply. |
| 000E54 (2019) |
Hasan Sat ; Gülce Ecem Can [Turquie] ; Reyhan Bilici Salman ; Asl Han Avano Lu Güler ; Hazan Karadeniz ; Abdurrahman Tufan | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register. |
| 000E55 (2019) |
Andrew N B. Weil [Royaume-Uni] | Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from a nationwide Swedish register. |
| 000E80 (2019) |
Shinji Maeda [Japon] ; Satoshi Osaga [Japon] ; Tomoyo Maeda [Japon] ; Norihisa Takeda [Japon] ; Shin-Ya Tamechika [Japon] ; Taio Naniwa [Japon] ; Akio Niimi [Japon] | Circulating Th17.1 cells as candidate for the prediction of therapeutic response to abatacept in patients with rheumatoid arthritis: An exploratory research |
| 000F22 (2019) |
Iain B. Mcinnes [Royaume-Uni] ; Gianfranco Ferraccioli [Italie] ; Maria-Antonietta D'Agostino [France] ; Manuela Le Bars [France] ; Subhashis Banerjee [États-Unis] ; Harris A. Ahmad [États-Unis] ; Yedid Elbez [France] ; Philip J. Mease [États-Unis] | Body mass index and treatment response to subcutaneous abatacept in patients with psoriatic arthritis: a post hoc analysis of a phase III trial |
